Home >
Medicine Info >
Bufatas Injection
Loading interface...

Bufatas Injection

Manufactured byINTAS PHARMACEUTICALS LTD
ContainsBusulfan
Description
Bufatas Injection is an anticancer agent, used in the treatment of various types of cancers of the blood and also used prior to stem cell transplantation. It should only be used under the supervision of a qualified physician. Close monitoring of kidney function and blood cell count is necessary while receiving this medication.
QUICK LINKS:
Side effectsConcernsUsage

Side effects

Major & minor side effects for Bufatas Injection

  • Difficulty in breathing
  • Jaundice
  • Chest pain
  • Blood in urine
  • Irregular heartbeat
  • Skin rash and itching
  • Fever or chills
  • Loss of appetite
  • Diarrhea
  • Headache
  • Dizziness
  • Back pain
  • Blurred vision

Uses of Bufatas Injection

What is it prescribed for?

  • Chronic myelogenous leukemia (CML)
  • Hematopoietic Stem Cell Transplantation
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of this medicine is cumulative which can be observed within 1-2 weeks after the initiation of the therapy.
  • How long do the effects of this medicine last?
    Since the effect of this medicine is cumulative, irrespective of its onset of action, Bufatas Injection remains active in the body up to 24 hours after administration.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Busulfan or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
General warnings

Bone marrow suppression

This medicine may cause bone marrow suppression which in turn lowers the white blood cell count (neutrophils) and platelets. Close monitoring of blood cell count is necessary. The baseline of the blood cell count should be obtained before initiation of the treatment. Do not start the treatment if the blood cell count is too low.

Seizures

This medicine may cause seizures in some patients. So extreme caution is required when administering Bufatas Injection in patients with a history of seizure disorder or head trauma. Pretreatment with an anticonvulsant drug is recommended prior to the therapy with this medicine.

Liver Disease

This medicine may increase the risk of toxic effects on the liver. Evaluation of liver function should be obtained before initiation of the treatment. Close monitoring of liver function is recommended during the treatment with this medicine.

Driving or Operating machinery

Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Laboratory tests

Your physician may perform appropriate laboratory tests for the confirmational diagnosis of chronic myelogenous leukemia, as this medicine is not recommended for use until the patient is definitively diagnosed with this condition.

Missed Dose

Oral: Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed dose. Injection: Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.

Overdose

Oral: Seek emergency medical treatment or contact the doctor in case of an overdose. Injection: Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Oxcarbazepine

Live attenuated vaccines and related products

Etanercept

Adalimumab

Clozapine

Disease interactions

Bone marrow suppression

This medicine should be used with extreme caution in patients suffering from bone marrow suppression which causes anemia and infections due to the increased risk of worsening of the patient's condition. Report any signs or symptoms suggesting infection such as bleeding or symptoms of anemia, fever, sore throat, or local infection to your doctor during the therapy with this medicine. Close clinical monitoring of hematopoietic function is recommended. An alternative treatment option should be considered in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Oral: Take this medicine as advised by the doctor. It should be given in multiple cycles along with other chemotherapy agents. It is important to receive every scheduled dose. The blood cells count should be assessed before starting the treatment. Report any unusual symptoms to the doctor on priority. Injection: This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

To be taken on an empty stomach

To be taken as instructed by doctor

May cause sleepiness

How it works
It works by interfering with the synthesis of DNA that causes the cancer cells to multiply. Thus, helps in stopping the growth and spread of cancer.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antineoplastics, Alkylating agents

Schedule

Schedule G

[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 7 December 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2

[Internet]. Medicines.org.uk. 2018 [cited 7 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/2235/smpc#

[Internet]. Medicines.org.uk. 2018 [cited 7 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/4653/smpc#

[Internet]. Ebs.tga.gov.au. 2018 [cited 7 December 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07356-3&d=201812071016933

[Internet]. Bccancer.bc.ca. 2018 [cited 7 December 2018]. Available from:

http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Busulfan%20monograph.pdf

[Internet]. 2018 [cited 7 December 2018]. Available from:

https://www.glowm.com/resources/glowm/cd/pages/drugs/b038.html
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 28 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.